Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Serina Therapeutics (SER) Shares Outstanding (Weighted Average) (2017 - 2025)

Serina Therapeutics' Shares Outstanding (Weighted Average) history spans 9 years, with the latest figure at $10.0 million for Q3 2025.

  • For Q3 2025, Shares Outstanding (Weighted Average) rose 48.1% year-over-year to $10.0 million; the TTM value through Sep 2025 reached $10.0 million, up 48.1%, while the annual FY2024 figure was $7.4 million, 229.26% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q3 2025 was $10.0 million at Serina Therapeutics, roughly flat from $10.0 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $37.9 million in Q1 2022 and bottomed at $1079.0 in Q4 2022.
  • The 5-year median for Shares Outstanding (Weighted Average) is $6.8 million (2024), against an average of $11.2 million.
  • The largest annual shift saw Shares Outstanding (Weighted Average) plummeted 100.0% in 2022 before it skyrocketed 392250.23% in 2024.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $37.9 million in 2021, then tumbled by 100.0% to $1079.0 in 2022, then skyrocketed by 207036.24% to $2.2 million in 2023, then skyrocketed by 229.26% to $7.4 million in 2024, then skyrocketed by 36.32% to $10.0 million in 2025.
  • Per Business Quant, the three most recent readings for SER's Shares Outstanding (Weighted Average) are $10.0 million (Q3 2025), $10.0 million (Q2 2025), and $9.8 million (Q1 2025).